𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck. $BCAX #ASCO26 Full video:

one in three alive at 3 years in 1L HPV-negative head and neck is a strong durability signal. that population does badly on immunotherapy alone, so the number is worth taking seriously. two things before the durability gets pinned on TGF-β. it is single arm phase 1/1b plus pembro, so you cannot separate what the TGF-β trap adds from EGFR and PD-1. and the doubling is against retrospective pembrolizumab, not a randomized arm. FORTIFI-HN01 settles both.